Hanall Biopharma Co., Ltd.

Creabilis Therapeutics S.p.a.

Hanall Pharmaceuticals, Co. Ltd

Catalyst Biosciences, Inc.

Hanall Pharmaceutical Company, Ltd.

Lila Drittanti

Thierry Guyon

Manuel Vega

Gilles Borrelly

Rene Gantier

Chiara Lorenzetto

Silvano Fumero

Luisa Bertarione Rava Rossa

Domenico Barone

Xavier Gallet

Barbara Canepa

Jorge Oyhenart

Domenico G Barone

Gilles Borrely

René Gantier

Provided are modified factor IX (FIX) polypeptides and methods of generating modified FIX polypeptides. Also provided are pharmaceutical compositions, including compositions formulation for oral administration, that contain the modified FIX polypeptides, and methods of treatment using modified FIX polypeptides.

Modified coagulation factor IX polypeptides and use thereof for treatment

Modified erythropoietin (EPO) polypeptides and other modified therapeutic polypeptides are provided. The EPO polypeptides and other therapeutic polypeptides are modified to exhibit physical properties and activities that differ from the unmodified EPO polypeptides and other unmodified therapeutic polypeptides, respectively. Nucleic acid molecules encoding these polypeptides also are provided. Also provided are methods of treatment and diagnosis using the polypeptides.

Modified erythropoietin polypeptides and uses thereof for treatment

Provided are modified growth hormone polypeptides, nucleic acid molecules encoding modified growth hormone polypeptides and methods of generating modified growth hormone polypeptides. Also provided are methods of treatment using modified growth hormone polypeptides.

Modified growth hormones that exhibit increased protease resistance and pharmaceutical compositions thereof

Modified erythropoietin polypeptides that include the mutation R131Q, and uses thereof are provided. Also provided are pharmaceutical compositions, including compositions formulated for oral administration, that contain the modified erythropoietin polypeptides and uses of the compositions to treat diseases and conditions treated by erythropoietin.

Protease resistant modified erythropoietin polypeptides

Protease resistant modified interferon-beta polypeptides, and pharmaceutical compositions containing such modified interferon-beta polypeptides are provided. The modified interferon-beta polypeptides contain amino acid substitutions that confer increased resistance to proteolysis over unmodified IFN beta cytokine molecules. The present invention provides for pharmaceutical formulations suitable for oral, nasal and pulmonary administration, and the use of such formulations in the treatment of disease.

Protease resistant modified IFN beta polypeptides and their use in treating diseases

The present invention relates to polypeptide variants of the HMGB-1 high affinity binding domain Box-A (HMGB1 Box-A) or to a biologically active fragment of HMGB1 Box-A, which are obtained through systematic mutations of single amino acids of the wild-type HMGB1 Box-A protein and which show an increased resistance to proteases and which are therefore characterized by more favorable pharmacokinetic and pharmacodynamic profiles. Moreover, the present invention concerns the use of said polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and associated with RAGE.

HMGB1 high affinity binding domain Box-A mutants

Protease resistant modified interferon-beta polypeptides, pharmaceutical compositions and methods of treatment administering the compositions are provided. The modified interferon-beta polypeptides are orally available; hence pharmaceutical compositions formulated for oral administration also are provided.

Protease resistant modified interferon-beta polypeptides

Protease resistant modified interferon-beta polypeptides, pharmaceutical compositions and methods of treatment by administering the compositions are provided. The modified interferon-beta polypeptides are orally available; hence pharmaceutical compositions formulated for oral administration also are provided.

Interferon-&#x3b2; mutants with increased anti-proliferative activity

Modified growth hormones

Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated by cytokines.

Protease resistant interferon beta mutants

Modified growth hormone

Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules

Processes and systems for the high throughput directed evolution of peptides and proteins, particularly those that act in complex biological settings, are provided. The proteins and peptides include, but are not limited to, intracellular proteins, messenger/signaling/hormone proteins and viral proteins. Also provided is a rational method for generating protein variants and also a method for titering viruses.

High throughput directed evolution by rational mutagenesis

Protease resistant mutant of human HMGB1 high affinity binding domain Box-A (HMGB1 Box-A)

Processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided is a rational method for generating protein variants and the resulting variants.

Growing community of inventors

Vigneux-sur-Seine, France

Lila Drittanti